A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...
CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation. EINPresswire/ -- CRISPR Gene Editing: A Technological Overview CRISPR gene editing has ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...
ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School ...
10d
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...
Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback